Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 4
1994 5
1995 4
1996 3
1997 5
1998 8
1999 5
2000 5
2001 5
2002 11
2003 19
2004 15
2005 18
2006 21
2007 14
2008 25
2009 23
2010 20
2011 9
2012 13
2013 16
2014 13
2015 12
2016 9
2017 19
2018 11
2019 20
2020 17
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

313 results
Results by year
Filters applied: . Clear all
Page 1
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.
Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C. Paczulla AM, et al. Among authors: dirnhofer s. Nature. 2019 Aug;572(7768):254-259. doi: 10.1038/s41586-019-1410-1. Epub 2019 Jul 17. Nature. 2019. PMID: 31316209 Free PMC article.
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC. Stivala S, et al. Among authors: dirnhofer s. J Clin Invest. 2019 Mar 4;129(4):1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4. J Clin Invest. 2019. PMID: 30730307 Free PMC article.
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC. Rao TN, et al. Among authors: dirnhofer s. Blood. 2019 Nov 21;134(21):1832-1846. doi: 10.1182/blood.2019000162. Blood. 2019. PMID: 31511238 Free PMC article.
[Reactive Lymphadenopathies].
Vallejo A, Menter T, Tzankov A, Dirnhofer S. Vallejo A, et al. Among authors: dirnhofer s. Ther Umsch. 2019;76(7):365-373. doi: 10.1024/0040-5930/a001111. Ther Umsch. 2019. PMID: 31913097 Review. German.
A pattern-based approach to reactive lymphadenopathies.
Tzankov A, Dirnhofer S. Tzankov A, et al. Among authors: dirnhofer s. Semin Diagn Pathol. 2018 Jan;35(1):4-19. doi: 10.1053/j.semdp.2017.05.002. Epub 2017 May 25. Semin Diagn Pathol. 2018. PMID: 28619469 Review.
Deciphering the genetic landscape of pulmonary lymphomas.
Vela V, Juskevicius D, Prince SS, Cathomas G, Dertinger S, Diebold J, Bubendorf L, Horcic M, Singer G, Zettl A, Dirnhofer S, Tzankov A, Menter T. Vela V, et al. Among authors: dirnhofer s. Mod Pathol. 2021 Feb;34(2):371-379. doi: 10.1038/s41379-020-00660-2. Epub 2020 Aug 27. Mod Pathol. 2021. PMID: 32855441
313 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page